ENABLEX

This brand name is authorized in Brazil, Canada, Ecuador, Hong Kong, New Zealand, United States, South Africa

Active ingredients

The drug ENABLEX contains one active pharmaceutical ingredient (API):

1 Darifenacin UNII CR02EYQ8GV - DARIFENACIN HYDROBROMIDE

Darifenacin is a selective muscarinic M3 receptor antagonist (M3 SRA) in vitro. The M3 receptor is the major subtype that controls urinary bladder muscle contraction. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome. Read about Darifenacin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ENABLEX Extended-release tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G04BD10	Darifenacin	G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics
Discover more medicines within G04BD10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 505614120040113, 505614120040613
Country: CA	Health Products and Food Branch	Identifier(s): 02273217, 02273225
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): H7171013, H7691013
Country: HK	Department of Health Drug Office	Identifier(s): 55414, 55415
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11407, 11408
Country: US	FDA, National Drug Code	Identifier(s): 0430-0170, 0430-0171
Country: ZA	Health Products Regulatory Authority	Identifier(s): A38/5.4/0700